UBT251, a novel triple GLP-1, GIP, and glucagon receptor agonist, in adults with type 2 diabetes: A multicenter, randomized phase 2 trial. // Cell Metabolism. – URL: https://www.sciencedirect.com/science/article/pii/S155041312600447X?dgcid=rss_sd_all
UBT251, a novel triple GLP-1, GIP, and glucagon receptor agonist, in adults with type 2 diabetes: A multicenter, randomized phase 2 trial. Cell Metabolism. https://www.sciencedirect.com/science/article/pii/S155041312600447X?dgcid=rss_sd_all
“UBT251, a novel triple GLP-1, GIP, and glucagon receptor agonist, in adults with type 2 diabetes: A multicenter, randomized phase 2 trial.” Cell Metabolism.
@article{article2605,
title = {UBT251, a novel triple GLP-1, GIP, and glucagon receptor agonist, in adults with type 2 diabetes: A multicenter, randomized phase 2 trial},
journal = {Cell Metabolism},
url = {https://www.sciencedirect.com/science/article/pii/S155041312600447X?dgcid=rss_sd_all}
}